N@N

Depomed to Present at Upcoming Conferences

^{Published on 2009-02-03 07:26:28, Last Modified on 2009-02-03 07:27:03 - Market Wire}
 

MENLO PARK, Calif.--([ BUSINESS WIRE ])--Depomed, Inc. (NASDAQ:DEPO) announced today that president and chief executive officer, Carl A. Pelzel will provide corporate presentations at the following upcoming conferences:

• BIO CEO and Investor Conference, February 10, 2009 at 11:15 a.m. PT
• Roth OC Growth Conference, February 17, 2009 at 12:00 p.m. PT

The company will be webcasting its presentations and interested parties can access the live or archived presentations for up to 90 days on the company's website at [ www.depomed.com ].

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm^TM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA^® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin^® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, [ www.depomedinc.com ].